Pharmacology · Cardiovascular

Atrial Fibrillation: Rate Control, Rhythm Control, and Cardioversion

Drug selection by cardiac substrate, cardioversion strategies, and peri-cardioversion anticoagulation

Rate control accepts atrial fibrillation and targets ventricular rate below 110 beats per minute (lenient) or below 80 (symptomatic) — favored in older patients with minimal symptoms or long-standing atrial fibrillation; AFFIRM and RACE trials showed no mortality advantage for rhythm control in this population; beta-blockers are first-line, diltiazem an alternative (avoid in heart failure with reduced ejection fraction), digoxin an adjunct.
Rhythm control is favored in significantly symptomatic patients, newly diagnosed atrial fibrillation within one year, or atrial fibrillation-induced cardiomyopathy; EAST-AFNET 4 (2020) demonstrated that early rhythm control within one year of diagnosis reduces cardiovascular events; drug selection is entirely governed by cardiac substrate.
Cardioversion strategies range from the pill-in-the-pocket approach (flecainide or propafenone for structurally normal hearts, always preceded by an atrioventricular nodal agent) to IV ibutilide for acute cardioversion (highest torsades de pointes risk, 4-hour monitoring mandatory) to dofetilide or amiodarone for patients with structural heart disease or heart failure.
Peri-cardioversion anticoagulation follows a strict duration rule: if atrial fibrillation has lasted under 48 hours, cardioversion may proceed after initiating anticoagulation; if over 48 hours or unknown duration, either 3 weeks of therapeutic anticoagulation beforehand or a transesophageal echocardiogram to exclude left atrial appendage thrombus is required; 4 weeks of post-cardioversion anticoagulation is mandatory regardless of strategy due to atrial stunning.
Long-term anticoagulation after cardioversion is based on CHA₂DS₂-VASc score — treat men scoring 2 or more, women scoring 3 or more; direct oral anticoagulants are preferred over warfarin for non-valvular atrial fibrillation.

Rate Control vs. Rhythm Control — When to Choose Each

Strategy

Rate Control

Accept atrial fibrillation; control ventricular rate only
Target: resting rate below 110 beats per minute (lenient); below 80 (symptomatic)
Favored in: older patients, minimal symptoms, long-standing atrial fibrillation, high drug toxicity risk
Agents: beta-blockers first-line; diltiazem alternative (avoid in heart failure with reduced ejection fraction); digoxin adjunct
AFFIRM and RACE trials: no mortality advantage over rate control for rhythm control in older patients

Strategy

Rhythm Control

Restore and maintain sinus rhythm
Favored in: significant symptoms, newly diagnosed atrial fibrillation (within 1 year), atrial fibrillation-induced cardiomyopathy, younger patients
EAST-AFNET 4 (2020): early rhythm control within 1 year of diagnosis reduced cardiovascular events
Drug selection governed entirely by cardiac substrate
Catheter ablation increasingly preferred in heart failure with reduced ejection fraction

Rhythm Control Drug Selection by Cardiac Substrate

Cardiac Substrate	Acceptable Agents	Contraindicated
No structural heart disease	Flecainide, propafenone, sotalol, dronedarone, amiodarone	None of the above
Coronary artery disease / prior myocardial infarction	Sotalol, dofetilide, amiodarone; dronedarone (preserved ejection fraction only)	Flecainide, propafenone
Heart failure with reduced ejection fraction	Amiodarone, dofetilide only	Flecainide, propafenone, sotalol, dronedarone
Left ventricular hypertrophy (wall thickness over 1.4 cm)	Amiodarone (preferred); sotalol, dofetilide (if corrected QT interval and renal function permit)	Flecainide, propafenone (relative contraindication)

Pharmacologic Cardioversion Strategies

Outpatient Strategy

Pill-in-the-Pocket

Flecainide or propafenone taken by patient at onset of atrial fibrillation episode
Only in structurally normal hearts with demonstrated in-hospital tolerance
Mandatory: atrioventricular nodal agent taken 30 to 60 minutes first to prevent 1:1 atrial flutter
Cardioversion within 2 to 6 hours in majority

Intravenous Acute

Ibutilide

Intravenous only; effective for recent-onset atrial fibrillation and atrial flutter
Atrial flutter responds better than atrial fibrillation
Torsades de pointes risk 4 to 8% — highest of any cardioversion agent
Mandatory 4-hour post-dose monitoring; correct electrolytes first

Heart Failure Safe / Multi-Use

Dofetilide and Amiodarone

Dofetilide: oral cardioversion over 24 to 48 hours; safe in heart failure with reduced ejection fraction; in-hospital initiation
Amiodarone: less effective acutely but provides simultaneous rate control; safe in structural heart disease; intravenous or oral

Peri-Cardioversion Anticoagulation

Atrial Fibrillation Under 48 Hours

Proceed with Anticoagulation Initiation

Low immediate thromboembolic risk (insufficient time for thrombus formation)
Cardioversion may proceed after initiating anticoagulation
Mandatory: at least 4 weeks post-cardioversion anticoagulation regardless of CHA2DS2-VASc score
Reason: atrial stunning — left atrium contracts ineffectively for weeks after cardioversion

Atrial Fibrillation Over 48 Hours or Unknown

Two Accepted Strategies

Strategy 1: 3 weeks therapeutic anticoagulation before cardioversion, then 4 weeks after
Strategy 2: transesophageal echocardiogram to exclude left atrial appendage thrombus, then immediate cardioversion, then 4 weeks after
The 4-week post-cardioversion period is mandatory for both strategies due to atrial stunning

Long-Term Anticoagulation Decision

After the mandatory 4-week post-cardioversion period, continue anticoagulation based on CHA2DS2-VASc score: congestive heart failure (1), hypertension (1), age 75 or older (2), diabetes (1), prior stroke or transient ischemic attack (2), vascular disease (1), age 65 to 74 (1), female sex (1). Treat men with score 2 or more, women with score 3 or more. Prefer direct oral anticoagulants over warfarin for non-valvular atrial fibrillation.

Suggested References

Author / Organization	Title	Source
Katzung BG, ed.	Basic and Clinical Pharmacology. 15th ed.	McGraw-Hill; 2021
Brunton LL, Knollmann BC, eds.	Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed.	McGraw-Hill; 2023
Wyse DG, Waldo AL, DiMarco JP, et al	A comparison of rate control and rhythm control in patients with atrial fibrillation (AFFIRM)	N Engl J Med. 2002;347(23):1825–1833
Van Gelder IC, Hagens VE, Bosker HA, et al	A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation (RACE)	N Engl J Med. 2002;347(23):1834–1840
Kirchhof P, Camm AJ, Goette A, et al	Early rhythm-control therapy in patients with atrial fibrillation (EAST-AFNET 4)	N Engl J Med. 2020;383(14):1305–1316
Joglar JA, Chung MK, Armbruster AL, et al	2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation	J Am Coll Cardiol. 2024;83(1):109–279
January CT, Wann LS, Calkins H, et al	2019 AHA/ACC/HRS focused update of the 2014 guideline for management of patients with atrial fibrillation	J Am Coll Cardiol. 2019;74(1):104–132
Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al	Dofetilide in patients with congestive heart failure and left ventricular dysfunction (DIAMOND-CHF)	N Engl J Med. 1999;341(12):857–865
Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ	Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach	Chest. 2010;137(2):263–272
Hindricks G, Potpara T, Dagres N, et al	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation	Eur Heart J. 2021;42(5):373–498
Marrouche NF, Brachmann J, Andresen D, et al	Catheter ablation for atrial fibrillation with heart failure (CASTLE-AF)	N Engl J Med. 2018;378(5):417–427
Stiell IG, Sivilotti MLA, Taljaard M, et al	Electrical versus pharmacological cardioversion for emergency department patients with acute atrial fibrillation (RAFF2)	Lancet. 2020;395(10221):339–349